FAERS analysis finds distinct reported safety signals for newer seizure drugs
Real-world safety profiles of newer antiseizure medications: A pharmacovigilance study based on FDA Adverse Event Reporting System database.
AI Summary
This pharmacovigilance study compared post-marketing adverse-event reports for four newer antiseizure medications, including cannabidiol (CBD). Researchers analyzed 13,763 reports submitted to the FDA Adverse Event Reporting System from 2016 through 2024. Across the medications, seizure-related events were frequently reported, and each drug had a distinct pattern: CBD was associated with gastrointestinal events, while the other medications showed different reported signals, including psychiatric, visual, and cardiac events.
The analysis also found that CBD-related gastrointestinal reports and fenfluramine-related cardiac reports showed dose-dependent patterns; children had higher reporting odds of seizure with CBD and brivaracetam, and polytherapy was associated with more reports of somnolence. These are patterns in spontaneous reports, not proof that a medication caused an event or a measure of how often events occur among users. Because the study relies on FAERS reports, it is vulnerable to underreporting and reporting biases; this abstract-based summary cannot establish causation or compare the actual risk of these medications in patients.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.